ANTI-CD27 ANTIBODIES
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
-
Citations
45 Claims
-
1. (canceled)
-
2. (canceled)
-
3. An antibody or antigen binding fragment thereof that binds to human CD27, wherein the antibody or antigen binding fragment comprises:
-
a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO;
1, wherein X1=M;
or an amino acid sequence differing from said sequence by 1, 2, or 3 conservative substitutions;b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO;
2, wherein X1=N, X2=T, X3=N and X4=T, or an amino acid sequence differing from said sequence by 1, 2, or 3 conservative substitutions;c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO;
3, wherein X1=M, or an amino acid sequence differing from said sequence by 1, 2, or 3 conservative substitutions;d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO;
4, wherein X1=M, or an amino acid sequence differing from said sequence by 1, 2, or 3 conservative substitutions;e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO;
5, wherein X1=D and X2=T, or an amino acid sequence differing from said sequence by 1, 2, or 3 conservative substitutions; andf) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO;
6, wherein X1=W, X2=N and X3=S, or an amino acid sequence differing from said sequence by 1, 2, or 3 conservative substitutions. - View Dependent Claims (21, 22, 23, 24, 25, 27, 28)
-
-
4. An antibody or antigen binding fragment thereof that binds to human CD27 comprising a light chain immunoglobulin variable region, a heavy chain immunoglobulin variable region or both a light chain and a heavy chain immunoglobulin variable region selected from the group consisting of:
-
a) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO;
7 or an amino acid sequence differing from SEQ ID NO;
7 by 1, 2, or 3 conservative substitutions and/or a variable light chain comprising the amino acid sequence of SEQ ID NO;
8 or an amino acid sequence differing from SEQ ID NO;
8 by 1, 2, or 3 conservative substitutions;b) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO;
9 or an amino acid sequence differing from SEQ ID NO;
9 by 1, 2, or 3 conservative substitutions and/or a variable light chain comprising the amino acid sequence of SEQ ID NO;
14 or an amino acid sequence differing from SEQ ID NO;
14 by 1, 2, or 3 conservative substitutions;c) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO;
32 or an amino acid sequence differing from SEQ ID NO;
32 by 1, 2, or 3 conservative substitutions and/or a variable light chain comprising the amino acid sequence of SEQ ID NO;
33 or an amino acid sequence differing from SEQ ID NO;
33 by 1, 2, or 3 conservative substitutions;d) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO;
34 or an amino acid sequence differing from SEQ ID NO;
34 by 1, 2, or 3 conservative substitutions and/or a variable light chain comprising the amino acid sequence of SEQ ID NO;
35 or an amino acid sequence differing from SEQ ID NO;
35 by 1, 2, or 3 conservative substitutions;e) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO;
39 or an amino acid sequence differing from SEQ ID NO;
39 by 1, 2, or 3 conservative substitutions and/or a variable light chain comprising the amino acid sequence of SEQ ID NO;
40 or an amino acid sequence differing from SEQ ID NO;
40 by 1, 2, or 3 conservative substitutions;f) an antibody or antigen binding fragment thereof comprising a variable heavy chain selected from the group consisting of SEQ ID Nos;
10-13 or an amino acid sequence differing from one of SEQ ID Nos;
10-13 by 1, 2, or 3 conservative substitutions and/or a variable light chain selected from the group consisting of any one of SEQ ID Nos;
15-18 or an amino acid sequence differing from one of SEQ ID Nos;
15-18 by 1, 2, or 3 conservative substitutions;g) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising the amino acid sequence of SEQ ID NO;
10 or an amino acid sequence differing from SEQ ID NO;
10 by 1, 2, or 3 conservative substitutions and/or a variable light chain comprising the amino acid sequence of SEQ ID NO;
15 or an amino acid sequence differing from SEQ ID NO;
15 by 1, 2, or 3 conservative substitutions;h) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising at least 90% identity to any one of SEQ ID Nos;
10-13 and/or a variable light chain comprising at least 90% identity to any one of SEQ ID Nos;
15-18;i) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising at least 90% identity to any one of SEQ ID Nos;
10-13 and/or a variable light chain comprising at least 90% identity to any one of SEQ ID Nos;
15-18, wherein any sequence variations occur in the framework regions of the antibody or antigen binding fragment;j) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions with respect to any one of SEQ ID Nos;
10-13 and/or a variable light chain comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions with respect to any one of SEQ ID Nos;
15-18; andk) an antibody or antigen binding fragment thereof comprising a variable heavy chain comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions with respect to any one of SEQ ID Nos;
10-13 and/or a variable light chain comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions with respect to any one of SEQ ID Nos;
15-18, wherein the amino acid substitutions occur in the framework regions of the antibody or antigen binding fragment. - View Dependent Claims (5)
-
-
6. (canceled)
-
7. (canceled)
-
8. (canceled)
-
9. (canceled)
-
10. (canceled)
-
11. (canceled)
-
12. (canceled)
-
13. An antibody or antigen binding fragment thereof that binds the same epitope of human CD27 as an antibody comprising the variable heavy chain of SEQ ID NO:
- 10 and the variable light chain of SEQ ID NO;
15;
or binds the same epitope of human CD27 as an antibody comprising the variable heavy chain of SEQ ID NO;
7 and the variable light chain of SEQ ID NO;
8.
- 10 and the variable light chain of SEQ ID NO;
- 14. An antibody or antigen binding fragment thereof, wherein, when bound to human CD27, binds at least one residue selected from the group consisting of Leu18, Asp34, Gln35, and Lys38 of SEQ ID NO:
-
20. (canceled)
-
26. (canceled)
-
29. (canceled)
-
30. (canceled)
-
31. (canceled)
-
32. (canceled)
-
33. (canceled)
-
34. (canceled)
-
35. (canceled)
-
36. (canceled)
-
37. (canceled)
-
38. (canceled)
-
39. (canceled)
-
40. (canceled)
-
41. (canceled)
-
42. (canceled)
-
43. (canceled)
-
44. (canceled)
-
45. (canceled)
Specification